CEL-SCI engages in the research and development of immunotherapies to improve the treatment of cancer and other diseases. CEL-SCI is developing an immunotherapy as a possible treatment for H1N1 hospitalized patients and as a vaccine for rheumatoid arthritis. The company’s investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. For more information visit the company’s Web site at www.cel-sci.com
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
Let us hear your thoughts below: